Omada Health, Inc. Common Stock (OMDA)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $889.00M
Last updated: Nov 17, 2026 at 11:05 AM ET
Omada Health, Inc. Common Stock (OMDA) Financials: Revenue, Profit and Cash Flow
Omada Health, Inc. Common Stock reported revenue of $260.21M for the fiscal year ended Dec 31, 2025, up 53.2% from the year before. That year, net income was -$12.78M with a net margin of -4.9%, operating cash flow was $18.25M and free cash flow was $12.42M. The quarter ended Sep 30, 2026 had revenue of $91.31M and net income of $6.55M.
Revenue and Margins
The operating margin was -4.6% in the fiscal year ended Dec 2025, the highest of the 4 years shown.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $260.21M | +53.2% | 65.7% | -4.6% | -4.9% |
| Dec 2024 | $169.80M | +38.3% | 60.6% | -25.7% | -27.8% |
| Dec 2023 | $122.78M | +37.7% | 57.0% | -53.8% | -55.0% |
| Dec 2022 | $89.19M | N/A | 48.0% | -81.1% | -81.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | $260.21M | $169.80M | $122.78M | $89.19M |
| Cost of revenue | $89.27M | $66.92M | $52.81M | $46.39M |
| Gross profit | $170.94M | $102.88M | $69.97M | $42.79M |
| Research and development | $40.68M | $35.92M | $33.74M | $26.17M |
| Operating income | -$11.97M | -$43.65M | -$66.00M | -$72.35M |
| Net income | -$12.78M | -$47.14M | -$67.51M | -$72.52M |
| EBITDA | -$4.33M | -$35.60M | -$60.38M | -$63.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $91.31M | $87.83M | $78.05M | $75.85M | $68.03M | $61.37M | $54.96M | $47.98M | $45.52M | $41.21M | $35.09M | $32.55M |
| Gross profit | $69.28M | $63.79M | $48.69M | $53.66M | $45.07M | $40.31M | $31.90M | $31.98M | $28.56M | $24.83M | $17.35M | $20.10M |
| Operating income | $4.82M | $3.55M | -$4.78M | $3.28M | -$2.51M | -$4.34M | -$8.40M | -$7.10M | -$8.52M | -$10.04M | -$17.99M | -$13.40M |
| Net income | $6.55M | $5.29M | -$2.97M | $5.16M | -$3.18M | -$5.31M | -$9.45M | -$8.25M | -$9.23M | -$10.69M | -$18.97M | -$13.93M |
Balance Sheet
As of Dec 2025, cash and equivalents of $222.04M were 72.7% of total assets of $305.41M, against total liabilities of $75.73M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total assets | $305.41M | $150.89M | $175.08M | $221.80M |
| Current assets | $272.93M | $113.06M | $142.88M | $188.56M |
| Cash and equivalents | $222.04M | $76.39M | $115.64M | $168.12M |
| Total liabilities | $75.73M | $86.26M | $76.16M | $66.19M |
| Short-term debt | N/A | $415.00K | $787.00K | $648.00K |
| Long-term debt | N/A | $29.77M | $29.38M | $28.89M |
| Shareholder equity | $229.68M | -$384.40M | $98.92M | $155.60M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $348.54M | $328.22M | $302.80M | $305.41M | $287.47M | $302.97M | $141.18M | N/A | N/A | N/A | N/A | N/A |
| Total liabilities | $75.38M | $75.48M | $68.68M | $75.73M | $70.12M | $88.76M | $82.20M | $535.29M | N/A | N/A | -$98.92M | N/A |
| Cash and equivalents | $243.15M | $221.71M | $211.76M | $222.04M | $198.63M | $223.15M | $59.40M | N/A | N/A | N/A | $115.67M | N/A |
| Shareholder equity | $273.16M | $252.74M | $234.12M | $229.68M | $217.35M | $214.21M | $58.98M | -$384.40M | N/A | N/A | $98.92M | N/A |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 68.1% of operating cash flow. Share repurchases came to 34.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating cash flow | $18.25M | -$34.18M | -$49.74M | -$68.98M |
| Capital expenditures | $5.83M | $3.86M | $2.92M | $2.72M |
| Free cash flow | $12.42M | -$38.04M | -$52.66M | -$71.70M |
| Share repurchases | $4.28M | $4.54M | $111.00K | N/A |
| Investing cash flow | -$5.83M | -$3.86M | -$2.92M | -$2.72M |
| Financing cash flow | $133.22M | -$1.21M | $179.00K | $16.32M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $15.14M | $4.01M | -$11.83M | $21.38M | $10.13M | $2.86M | -$16.12M | -$6.49M | $1.06M | -$8.10M | -$20.65M |
| Capital expenditures | $1.63M | $1.66M | $1.56M | $1.35M | $1.99M | $1.25M | $1.25M | $969.00K | $1.07M | $1.04M | $781.00K |
| Free cash flow | $13.51M | $2.34M | -$13.39M | $20.03M | $8.15M | $1.61M | -$17.37M | -$7.46M | -$12.00K | -$9.15M | -$21.43M |
Frequently Asked Questions About OMDA
What is Omada Health, Inc. Common Stock's annual revenue?
Omada Health, Inc. Common Stock reported revenue of $260.21M for the fiscal year ended Dec 31, 2025.
How fast is Omada Health, Inc. Common Stock's revenue growing?
Revenue was up 53.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 42.9%.
Is Omada Health, Inc. Common Stock profitable?
No. Omada Health, Inc. Common Stock reported net income of -$12.78M for the fiscal year ended Dec 31, 2025, with a net margin of -4.9%.
How much free cash flow does OMDA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $18.25M minus capital expenditures of $5.83M produced free cash flow of $12.42M.
How much debt does Omada Health, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $222.04M.
OMDA pages: Overview, Forecast, Financials, Valuation, Competitors